Tri Locum Partners LP Takes $19.93 Million Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Tri Locum Partners LP purchased a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 161,812 shares of the specialty pharmaceutical company's stock, valued at approximately $19,927,000. Jazz Pharmaceuticals comprises 4.1% of Tri Locum Partners LP's holdings, making the stock its 11th largest holding. Tri Locum Partners LP owned 0.27% of Jazz Pharmaceuticals at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Fuller & Thaler Asset Management Inc. raised its stake in shares of Jazz Pharmaceuticals by 117.4% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company's stock worth $115,681,000 after purchasing an additional 507,234 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Jazz Pharmaceuticals by 18.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock worth $250,619,000 after purchasing an additional 320,724 shares during the last quarter. GMT Capital Corp raised its holdings in shares of Jazz Pharmaceuticals by 140.0% in the 4th quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company's stock valued at $62,659,000 after purchasing an additional 296,800 shares during the period. Pacer Advisors Inc. lifted its stake in Jazz Pharmaceuticals by 5.5% in the 4th quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company's stock valued at $272,713,000 after purchasing an additional 115,102 shares during the last quarter. Finally, Capital World Investors grew its holdings in Jazz Pharmaceuticals by 5.7% during the fourth quarter. Capital World Investors now owns 1,923,342 shares of the specialty pharmaceutical company's stock worth $236,860,000 after purchasing an additional 104,195 shares during the period. Institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ traded up $3.07 during midday trading on Friday, hitting $120.25. The company's stock had a trading volume of 398,317 shares, compared to its average volume of 802,257. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a one year low of $95.49 and a one year high of $148.06. The stock has a market capitalization of $7.41 billion, a price-to-earnings ratio of 16.93, a price-to-earnings-growth ratio of 1.04 and a beta of 0.42. The company's fifty day simple moving average is $123.02 and its two-hundred day simple moving average is $122.40.

Analyst Ratings Changes

A number of analysts have recently issued reports on JAZZ shares. Morgan Stanley reaffirmed an "overweight" rating and issued a $183.00 price objective (up from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. Wells Fargo & Company raised Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their target price for the stock from $130.00 to $170.00 in a report on Thursday, February 13th. JPMorgan Chase & Co. boosted their target price on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Needham & Company LLC reaffirmed a "buy" rating and set a $210.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, April 10th. Finally, Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and boosted their price objective for the company from $140.00 to $150.00 in a report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $187.71.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the company's stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $123.75, for a total transaction of $185,625.00. Following the completion of the transaction, the chief executive officer now directly owns 440,307 shares in the company, valued at approximately $54,487,991.25. This represents a 0.34 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Neena M. Patil sold 3,800 shares of the firm's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total value of $550,506.00. Following the sale, the executive vice president now directly owns 33,318 shares in the company, valued at approximately $4,826,778.66. This trade represents a 10.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 28,736 shares of company stock worth $4,023,305 over the last 90 days. Insiders own 4.20% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.